Inflammatory myofibroblastic tumour of an unusual presentation in the uterine cervix: a case report.
Cervical tumour
Gynaecologic tumour
Inflammatory myofibroblastic tumour
Mesenquimal neoplasia
Soft tissue sarcoma
Journal
World journal of surgical oncology
ISSN: 1477-7819
Titre abrégé: World J Surg Oncol
Pays: England
ID NLM: 101170544
Informations de publication
Date de publication:
20 Nov 2021
20 Nov 2021
Historique:
received:
15
07
2021
accepted:
01
11
2021
entrez:
21
11
2021
pubmed:
22
11
2021
medline:
24
11
2021
Statut:
epublish
Résumé
Inflammatory myofibroblastic tumour is an infrequent mesenchymal neoplasia of unknown aetiology and variable behaviour, ranging from rather benign lesions to locally aggressive and even metastatic disease. Its presence has been described in almost all organs; however, its location in the female genital tract has rarely been reported. We present the case of a 47-year-old female, who was studied in our institution for a recent medical history of several weeks of dyspareunia and abdominal pain. She underwent pertinent studies including ultrasonography and CT scan. Under suspicion of degenerated leiomyoma, a total hysterectomy was performed. Unexpectedly, the pathological study of the surgical specimen showed very few tumour cells with focal fusiform morphology surrounded by an abundant inflammatory infiltrate; a thorough immunohistochemistry study lead to myofibroblastic tumour of the cervix diagnosis. A PET-CT scan did not show metastatic disease. The patient did not undergo any adjuvant treatment, and she is currently on surveillance with no evidence of disease relapse. Inflammatory myofibroblastic tumour remains a rare entity yet to be fully elucidated. The diagnosis is based on pathological study due to the lack of typical clinical manifestations and typical radiological images. Surgical resection is the most frequent treatment, whereas chemotherapy and radiotherapy are restricted to locally advanced or metastatic disease. Tirosine kinase inhibitor crizotinib has shown promising results especially in tumours harbouring ALK mutation.
Sections du résumé
BACKGROUND
BACKGROUND
Inflammatory myofibroblastic tumour is an infrequent mesenchymal neoplasia of unknown aetiology and variable behaviour, ranging from rather benign lesions to locally aggressive and even metastatic disease. Its presence has been described in almost all organs; however, its location in the female genital tract has rarely been reported.
CASE PRESENTATION
METHODS
We present the case of a 47-year-old female, who was studied in our institution for a recent medical history of several weeks of dyspareunia and abdominal pain. She underwent pertinent studies including ultrasonography and CT scan. Under suspicion of degenerated leiomyoma, a total hysterectomy was performed. Unexpectedly, the pathological study of the surgical specimen showed very few tumour cells with focal fusiform morphology surrounded by an abundant inflammatory infiltrate; a thorough immunohistochemistry study lead to myofibroblastic tumour of the cervix diagnosis. A PET-CT scan did not show metastatic disease. The patient did not undergo any adjuvant treatment, and she is currently on surveillance with no evidence of disease relapse.
CONCLUSIONS
CONCLUSIONS
Inflammatory myofibroblastic tumour remains a rare entity yet to be fully elucidated. The diagnosis is based on pathological study due to the lack of typical clinical manifestations and typical radiological images. Surgical resection is the most frequent treatment, whereas chemotherapy and radiotherapy are restricted to locally advanced or metastatic disease. Tirosine kinase inhibitor crizotinib has shown promising results especially in tumours harbouring ALK mutation.
Identifiants
pubmed: 34801049
doi: 10.1186/s12957-021-02438-5
pii: 10.1186/s12957-021-02438-5
pmc: PMC8606074
doi:
Substances chimiques
Crizotinib
53AH36668S
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
331Informations de copyright
© 2021. The Author(s).
Références
Stem Cell Res Ther. 2021 Aug 3;12(1):434
pubmed: 34344478
Eur J Cancer. 2019 Mar;109:192-195
pubmed: 30655100
Iran J Radiol. 2016 Jan 30;13(1):e12991
pubmed: 27110328
Medicine (Baltimore). 2017 Dec;96(48):e8974
pubmed: 29310405
Am J Obstet Gynecol. 2003 Sep;189(3):890-1
pubmed: 14526339
N Engl J Med. 2010 Oct 28;363(18):1727-33
pubmed: 20979472
Cancer Discov. 2014 Aug;4(8):889-95
pubmed: 24875859
J Hematol Oncol. 2015 Jun 11;8:66
pubmed: 26062823
Mod Pathol. 2017 Oct;30(10):1489-1503
pubmed: 28664932
Am J Surg Pathol. 2017 Oct;41(10):1433-1442
pubmed: 28731868
Stem Cell Res Ther. 2020 Oct 23;11(1):452
pubmed: 33097078
AJR Am J Roentgenol. 2012 Mar;198(3):W217-27
pubmed: 22358018
Am J Surg Pathol. 2015 Feb;39(2):157-68
pubmed: 25321329
Cold Spring Harb Perspect Biol. 2018 Apr 2;10(4):
pubmed: 28432134
Lancet Respir Med. 2018 Jun;6(6):431-441
pubmed: 29669701
Pathol Int. 2006 Oct;56(10):625-8
pubmed: 16984620
Int J Gynecol Pathol. 2020 Mar;39(2):152-156
pubmed: 30741845
Semin Diagn Pathol. 1998 May;15(2):85-101
pubmed: 9606801
Am J Surg Pathol. 2005 Oct;29(10):1348-55
pubmed: 16160478
Arch Pathol Lab Med. 2019 Jan;143(1):122-129
pubmed: 29965784
J Clin Oncol. 2015 Jan 10;33(2):e7-e10
pubmed: 24590652
Gynecol Oncol Case Rep. 2013 Jul 30;6:39-41
pubmed: 24371717
Am J Surg Pathol. 2007 Apr;31(4):509-20
pubmed: 17414097
Int J Gynecol Pathol. 1987;6(3):275-86
pubmed: 3429108
Wound Repair Regen. 2016 Mar;24(2):215-22
pubmed: 26704519
J Clin Pathol. 2008 Apr;61(4):428-37
pubmed: 17938159
J Int Med Res. 2018 Aug;46(8):3498-3503
pubmed: 29900760
Eur J Obstet Gynecol Reprod Biol. 2011 Aug;157(2):234-6
pubmed: 21439710